Personalized Medicine and Genetics
In 2016, realizing that healthcare services of the future will be personalized, predictive and preventive, CTS opened its genetics and personalized medicine business unit and has been investing in this area ever since.
Since then, we have created partnerships with leading innovative companies around the world, where clinical evidence has shown the quality and efficacy of the tests in better risk management, personalized care and ultimately their contribution to improved outcomes.
Our long-standing relationships with doctors (via medical science liaison reps); with patients (via our service hotline); and our collaboration with local and foreign laboratories, help us to support patients and caregivers in their quest to better understand their personal health profile, and ultimately get personalized optimal treatment.
We offer genetic testing kits and services for:
-
NIPT – MaterniT & GenomiT - Non Invasive Prenatal Test
-
Afirma (Veracyte) - Thyroid FNA analysis (contributes to improving diagnosis and treatment of thyroid nodules)
-
Endopredict (Myriad) for Breast Cancer
-
GenWise and myRisk (Myriad) for the assessment of hereditary cancer risk
-
Prolaris (Myriad) for Prostate Cancer risk management
-
Neuropharmagen (AB biotics) – Identifying the safest and most appropriate psychotropic medication for each patient, by analyzing their DNA
Our Partners Include:
-
Sividon diagnostics (acquired by Myriad)
- Veracyte